NCT06487468Completed
Risk Factors In Heart Failure Patients With Preserved Ejection Fraction
A Study on Risk Factors in Heart Failure Patients With Preserved Ejection Fraction After Hospital Discharge
Source: ClinicalTrials.gov · Last updated 8 Jul 2024
Brief summary (registry, in English)
This study aimed to identify the independent risk factors associated with heart failure readmission, cardiac mortality and all-cause death among patients discharged from Xiangtan Central Hospital with heart failure and preserved ejection fraction (HFpEF). Understanding related risk factors might add future clinical decision making for individualized post discharge management of HFpEF patients aiming to improve the outcome of discharged HFpEF patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 9419 (actual)
- First submitted
- 27 Jun 2024
- Start date
- 1 May 2014
- Primary completion date
- 31 Jan 2023
- Lead sponsor
- Xiangtan Central Hospital
- Diseases
- Heart failure
- NCT number
- NCT06487468
What you commit to
- Study type: Observational
- Participants enrolled: 9419
- From 1 May 2014 to the primary completion date, 31 Jan 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- 1\) age under 18 years; 2) life expectancy of less than one year due to non-cardiac conditions.
Who the study is looking for
- Patients discharged with diagnosis of heart failure were screened and met definition of heart failure with preserved ejection fraction (HFpEF) according to the 2021 European Society of Cardiology (ESC) guidelines at final analysis.
- 1）Heart failure signs and symptoms; 2）LVEF\>50%;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.